Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Scilex Holding Company (NASDAQ:SCLX, ", Scilex", ))))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC:SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, is providing certain preliminary unaudited financial results for the month ended May 31, 2023, and year-to-date as of May 31, 2023, based on currently available information.
Scilex estimates that ZTlido gross sales for May 2023 were in the range of $13.0 million to $15.0 million, compared to $8.5 million in May 2022, representing growth in the range of 53% to 76%; year-to-date May 2023 gross sales were in the range of $49.2 million to $54.3 million, compared to $32.0 million for year-to-date May 2022, representing growth in the range of 54% to 70%.
Scilex further estimates that net sales for May 2023 were in the range of $4.2 million to $5.1 million, compared to net sales of $2.8 million in May 2022, representing growth in the range of 50% to 82%; year-to-date May 2023 net sales were in the range of $16.0 million to $19.0 million, compared to $11.4 million for year-to-date May 2022, representing growth in the range of 40% to 67%.
This preliminary financial data has been prepared by and is the responsibility of Scilex. Scilex has not fully completed its review of these preliminary financial results for the one month ended May 31, 2023, and year-to-date as of May 31, 2023. Scilex's independent auditor has not reviewed or audited these preliminary estimated financial results. Scilex's actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.